Evidence mapPaperPMID 40544900Full record

ArticleJournal of biomedical informatics2025

KGiA: Drug repurposing through disease-aware knowledge graph augmentation.

Çerağ Oğuztüzün, Zhenxiang Gao, Hui Li, Rong Xu

Abstract read
In one paragraph

Article in Journal of biomedical informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Çerağ OğuztüzünCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University, 10900 Euclid Ave, Cleveland, 44106, OH, USA; Department of Computer Science, Case Western Reserve University, 10900 Euclid Ave, Cleveland, 44106, OH, USA.
Zhenxiang GaoCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University, 10900 Euclid Ave, Cleveland, 44106, OH, USA.
Hui LiCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University, 10900 Euclid Ave, Cleveland, 44106, OH, USA.
Rong XuCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University, 10900 Euclid Ave, Cleveland, 44106, OH, USA. Electronic address: rxx@case.edu.

Funding

Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's DiseaseR01AG061388 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI CHEN, SHU G., XU, RONG · 2018 to 2022
$3.4M
An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's DiseaseR01AG057557 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2017 to 2021
$2.8M
Rapid reverse translational drug repositioningDP2HD084068 · NICHD · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2014 to 2014
$2.4M
NIA NIH HHS R01 AG057557NIA NIH HHS R01 AG061388NICHD NIH HHS DP2 HD084068
6 · The paper itself

Abstract

objectiveDrug repurposing offers a cost-effective strategy to accelerate drug development by identifying new therapeutic uses for approved medications. Knowledge graphs (KGs) that capture large amounts of biomedical knowledge have recently been used for drug repurposing, however, KGs are inherently incomplete due to our limited biomedical knowledge.

methodsWe propose KGiA, an inductive graph augmentation method that supports semi-inductive reasoning-allowing models to generalize to previously unseen biomedical entities. KGiA enhances KGs using counterfactual relationships mined from disease-specific topological patterns. We apply it to a state-of-art biomedical KG constructed from six datasets including biomedical relationships extracted from biomedical literature, which comprised 1,614,801 triples and 100,563 entities, including 30,006 diseases.

resultsAcross five augmented architectures, KGiA improves generalizability by up to 24×in Mean Reciprocal Rank (MRR) and outperforms the state-of-the-art KG-based drug repurposing model by up to 32%. We applied KGiA in four case studies of diseases including Alzheimer's Disease and showed its promise in identifying novel repurposed candidate drugs.

conclusionWe showed that leveraging counterfactual relationships derived from disease-specific graph structures to augment existing knowledge graphs improved performance in KG-based drug repurposing.

Indexed as

Drug RepositioningAlgorithmsAlzheimer DiseaseData MiningHumansKnowledge BasesAlzheimer’s diseaseCounterfactual relationshipsDrug repurposingFine tuningFoundation modelsGraph augmentationGraph topologyInductive reasoningKnowledge graphs

Identifiers

PMID40544900
PMCPMC13131992

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.